DEVELOPMENT OF A MOUSE MODEL OF ALLERGIC RHINITIS AND BRONCHIAL ASTHMA CAUSED BY WORMWOOD POLLEN
Relevance. The prevalence of IgE-mediated allergic diseases among the population of industrially developed countries has reached 35%, and experts estimate that it will increase further in the next decade. Allergen-specific immunotherapy (SIT) is the only therapeutic approach capable of changing the natural course of the allergic process. Global prevalence of allergic diseases and several disadvantages of commercially available SIT products, made us start the search for new and improved specific treatment of allergies, which in turn requires the proper modeling of allergic diseases using laboratory animals.
Aim. Modeling of IgE-mediated bronchial asthma and allergic rhinitis in mice for future development of a new vaccine for allergen-specific immunotherapy.
Materials and Methods. Study design – experimental preclinical prospective cohort study. The entire cycle of work with laboratory animals was carried out at M. Aikimbayev National Research Center for Especially Dangerous Infections of the Ministry of Health of the Republic of Kazakhstan from September 2020 to January 2021. To model IgE-mediated bronchial asthma 8-12 week old SPF Balb/c female mice were used. Mice were sensitized by intranasal (IN) and intraperitoneal (IP) ways with 3 different extracts: bitter wormwood, common wormwood and their mix. Our choice of these particular allergens is determined by their significance in the ethiology of seasonal pollinosis in Kazakhstan. When assessing the level of sensitization of mice, a comprehensive approach was used, which included the analysis of antibody and cytokine levels, cellular immune responses, clinical signs and histological analysis of the lungs. Generally accepted methods of statistical processing of experimentally obtained samples of varying variables were used. The mean value of the sample (X) and the standard error (m) were determined. The reliability of the differences between the indicators and the groups was determined using the Graph Pad Prism 8 statistical program (Graph Pad Software, Inc., La Jolla, CA, USA).
Novelty: Modeling of allergic rhinitis and bronchial asthma with IN and IP regimes of sensitization with the use of bitter wormwood and common wormwood extracts and their mix in mice was tested for the first time.
Results: Among the allergens tested, common wormwood extract in the intraperitoneal sensitization had shown the most potent sensitizing effect: high values of total and antigen-specific IgE antibodies; pronounced polarization of immune response toward Th2 by the ratio of IgG1/IgG2a antibodies; positive reaction in the allergy ear swelling test; induced perivascular and eosinophilic inflammation in the lungs with expression of the allergic proinflammatory cytokine IL-5.
Conclusions: In modeling of IgE-mediated bronchial asthma in mice, common wormwood extract with intraperitoneal sensitization has the most potent sensitizing effect.
Мeruert Е. Babayeva1,3, https://orcid.org/0000-0001-8694-5942,
Kairat K. Tabynov1,2, https://orcid.org/0000-0001-9411-7952,
Тair Т. Nurpeissov3, https://orcid.org/0000-0002-9590-8905,
Kaissar K. Tabynov1,2, https://orcid.org/0000-0001-5823-1280
1 International Center for Vaccinology, Kazakh National Agrarian Research University,
Almaty, Republic of Kazakhstan;
2 Preclinical Research Laboratory With Vivarium, M. Aikimbayev National Research Center for Especially Dangerous Infections, Almaty, Republic of Kazakhstan;
3 Department of General Immunology, Asfendiyarov Kazakh National Medical University,
Almaty, Republic of Kazakhstan.
1. Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н. Место аллергенспецифической иммунотерапии в лечении атопии. Эффективная фармакотерапия // Аллергология и иммунология. 2012, №1. С. 6-16.
2. Курбачева О.М. Клинические, патогенетические и экономические аспекты применения аллерген-специфической иммунотерапии. Дисс. докт.мед.наук. М., 2007. 247с.
3. Adkinson N.F., Yunginger J.W., Busse W.W. et al. Middleton's Allergy, Principles and Practice. Mosby, 2003. P. 465-478.
4. Akdis C., Papadopoulos N., Cardona V. Fighting allergies beyond symptoms: the European Declaration on immunotherapy // European Journal of Immunology, 2011. P. 2802–2804.
5. Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy // Journal of Allergy and Clinical Immunology, 2011. P. 18-27.
6. Asher I., Baena-Cagnani C., Boner A., et al. World Allergy Organization guidelines for prevention of allergy and allergic asthma // International Archives of Allergy and Immunology, 2004. P. 83–92.
7. Bates J.H., Irvin C.G. Measuring lung function in mice: the phenotyping - uncertainty principle // J Appl Physiol, 2003. P. 1297-1306.
8. Bousquet J., Khaltaev N., Cruz A.A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) // Allerg, 2008. P. 8–16.
9. Braun A., Tschernig T. Animal regimels of asthma: Innovative methods of lung research and new pharmacological targets // Exp Toxic Pathol. 2006. P.3-4.
10. Brożek J.L., Bousquet J., Agache I., Agarwal A., Bachert C., Bosnic-Anticevich S. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, 2016 revision // J Allergy Clin Immunol. 2017. P.950-958.
11. Canonica G., Bosquet J., Casale T., et al. Sublingual Immunotherapy: World Allergy Organization Position Paper, 2009. P 1–5.
12. Canonica G.W., Cox L., Pawankar R., Baena-Cagnani C.E., Blaiss M. et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update // World Allergy Organization Journal, 2014. P 13-14.
13. Epstein M.M. Are mouse regimels of allergic asthma useful for testing novel therapeutics? // J Exp and Toxic Pathol, 2006. P. 41-44.
14. Epstein M.M. Do mouse regimels of allergic asthma mimic clinical disease? // Int Arch Allergy Immunol. 2004, v. 133(1), p.84-100.
15. Gelfand E.W. Mice are a good regimel of human airway disease // Am J Respir Crit Care Med, 2002. P. 5-8.
16. Grewling Ł, Bogawski P, Kostecki Ł, Nowak M, Szymańska A, Frątczak A. Atmospheric exposure to the major artemisia pollen allergen (Art v 1): Seasonality, impact of weather, and clinical implications // Sci Total Environ,2020.136611.
17. Hanneke P.M. Van der Kleij H.P., Kraneveld A.D., Kool M. et all. Murine Regimel for non IgE-mediated asthma // J Inflammation, 2004. №3. P. 115-125.
18. Jutel M., Agache I., Bonini S., Burks A.W., Calderon M., Canonica W. et al. International consensus on allergy immunotherapy // Allergy Clin Immunol, 2015. P.556-568.
19. Kips J.C., Anderson G.P., Herz U., Imman M.D., Jordana M., Kemmeny D.M., Lotvall J., Pauwels R.A., Sterk P.J., Van Oosterhout A.J., Chung K.F. Murine regimels of asthma // Eur Respir J., 2003. P.374-382.
20. Kobzar V. Pollen pollution strategy of artemisia and chenopodiaceae // Bull Sci Practice, 2021. P.10–28.
21. Linneberg A., Dam Petersen K., Hahn-Pedersen J., Hammerby E., Serup-Hansen N. and Boxall N. Burden of allergic respiratory disease: a systematic review // Clin Mol Allergy, 2016. P.14.
22. Pavlova NV ed. Flora of Kazakhstan. Alma-Ata: Publishing House of the Academy of Sciences of the Kazakh. SSR, 1996. P.154
23. Sánchez-Borges M., Martin B.L., Muraro A.M., Wood R.A., Agache I.O., Ansotegui I.J., et al. The Importance of Allergic Disease in Public Health: An iCAALL Statement // World Allergy Organ J., 2018.P.8.
24. Siniscalco C, Caramiello R, Migliavacca M, Busetto L, Mercalli L, Colombo R, et al. Models to predict the start of the airborne pollen season // Int J Biometeorol, 2015. P.837–848.
25. Strachan D., Sibbald B., Weiland S., et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) // Pediatric Allergy and Immunology, 1997. P. 161–176.
References: [1,2]
1. Astaf'eva N.G., Gamova I.V., Udovichenko E.N. Mesto allergenspetsificheskoi immunoterapii v lechenii atopii. Effektivnaya farmakoterapiya [The place of allergen-specific immunotherapy in the treatment of atopy. Effective pharmacotherapy]. Allergologiya i immunologiya [Allergology and Immunology]. 2012. №1. pp.6-16. [In Russian]
2. Kurbacheva O.M. Klinicheskie, patogeneticheskie i ekonomicheskie aspekty primeneniya allergen-spetsificheskoi immunoterapii: diss. dokt med.nauk. [Clinical, pathogenetic and economic aspects of the use of allergen-specific immunotherapy. Doct. diss.] 2007. 247 p. [In Russian]
Number of Views: 92
Category of articles:
Original articles
Bibliography link
Бабаева М.Е., Табынов К.К., Нурпеисов Т.Т., Табынов Кайс.К. Разработка мышиной модели аллергического ринита и бронхиальной астмы, вызываемые пыльцой полыни // Наука и Здравоохранение. 2022. 6(Т.24). С. 277-288. doi 10.34689/SH.2022.24.6.033Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS